Australia markets open in 3 hours 51 minutes
  • ALL ORDS

    6,818.10
    +21.20 (+0.31%)
     
  • AUD/USD

    0.6801
    -0.0069 (-1.00%)
     
  • ASX 200

    6,629.30
    +16.70 (+0.25%)
     
  • OIL

    99.59
    -8.84 (-8.15%)
     
  • GOLD

    1,766.20
    -35.30 (-1.96%)
     
  • BTC-AUD

    30,046.94
    +728.14 (+2.48%)
     
  • CMC Crypto 200

    440.98
    +0.95 (+0.22%)
     

GeNeuro: Availability of Documents and Information for the Annual Shareholders’ Meeting of May 31, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GENEVA, May 10, 2022--(BUSINESS WIRE)--Regulatory News:

GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), informs its shareholders that the 2022 Annual General Meeting will be held on Tuesday May 31, 2022 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.

Based on article 27 of Ordinance 3 on Measures to combat the Coronavirus of 19 June 2020 (COVID-19 Ordinance 3, status as of May 2, 2022), the Board of Directors has decided that shareholders of the Company may exercise their rights at this Ordinary General Meeting exclusively through the Independent Proxy. The conduct of the Ordinary General Meeting remains subject to additional measures that may be issued by the Swiss authorities.

The notice for the meeting, including the agenda of the day as well as the motions put to the vote, has been published today in the Feuille Officielle Suisse du Commerce.

The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: www.geneuro.com, under the section Investors / Documentation / Shareholders meeting.

It is also possible to consult the documents at the Company’s headquarters, chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates. Each shareholder has the right to request a hard copy of those documents.

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.

For more information, visit: www.geneuro.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006008/en/

Contacts

GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 48 00
investors@geneuro.com

NewCap (France)
Louis-Victor Delouvrier /
Mathilde Bohin (investors)
+33 1 44 71 98 52

Arthur Rouillé (media)
+33 1 44 71 00 15
geneuro@newcap.eu

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting